secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001171843-26-000810
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech Q1 FY2026 net loss $2.2M; progresses EB06 vitiligo Phase 2 prep
-----------------------------------------------------------------------------

- Net loss of $2.2M ($0.28/share) vs. $1.6M ($0.48/share) a year ago; operating expenses $2.3M.
- Cash and equivalents $12.1M; working capital $12.0M at Dec 31, 2025.
- EB06 (anti-CXCL10) manufacturing underway for Phase 2 vitiligo study; patient enrollment targeted mid-2026.
- Paridiprubart Phase 3 ARDS data under subgroup analysis; plans to present at scientific conferences.
- Participating in GVFS, BIO Europe Spring, ATS 2026 and other conferences March-May 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326000810/0001171843-26-000810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326000810/f8k_021226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer